Il programma di lavori preliminari fa avanzare l’ingegneria e l’approvvigionamento per la struttura FOAK di Aduro e stabilisce un percorso di esecuzione per la diffusione industriale della tecnologia Hydrochemolytic™, attraverso un approccio strutturato a fasi successive

Il programma di lavori preliminari fa avanzare l’ingegneria e l’approvvigionamento per la struttura FOAK di Aduro e stabilisce un percorso di esecuzione per la diffusione industriale della tecnologia Hydrochemolytic™, attraverso un approccio strutturato a fasi successive

Originally published via Source Article.

Das Programm für die Vorarbeiten bringt die ingenieurtechnische Planung und Beschaffung für die FOAK-Anlage von Aduro voran und schafft mit einem strukturierten, stufenweisen Entwicklungsansatz einen Umsetzungspfad für den industriellen Einsatz der Hydrochemolytic™-Technologie

Das Programm für die Vorarbeiten bringt die ingenieurtechnische Planung und Beschaffung für die FOAK-Anlage von Aduro voran und schafft mit einem strukturierten, stufenweisen Entwicklungsansatz einen Umsetzungspfad für den industriellen Einsatz der Hydrochemolytic™-Technologie

Originally published via Source Article.

Le programme de travaux préliminaires fait progresser l’ingénierie et l’approvisionnement de l’installation première du genre d’Aduro, et établit une trajectoire d’exécution pour le déploiement industriel de la technologie Hydrochemolytic™ selon une approche de structurée et jalonnée

Le programme de travaux préliminaires fait progresser l’ingénierie et l’approvisionnement de l’installation première du genre d’Aduro, et établit une trajectoire d’exécution pour le déploiement industriel de la technologie Hydrochemolytic™ selon une approche de structurée et jalonnée

Originally published via Source Article.

Het Early Works-programma bevordert de engineering en inkoop voor Aduro’s FOAK-faciliteit en legt via een gestructureerde, gefaseerde ontwikkelaanpak de basis voor de industriële toepassing van Hydrochemolytic™ Technology

Het Early Works-programma bevordert de engineering en inkoop voor Aduro’s FOAK-faciliteit en legt via een gestructureerde, gefaseerde ontwikkelaanpak de basis voor de industriële toepassing van Hydrochemolytic™ Technology

Originally published via Source Article.

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company’s public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

Originally published via Source Article.

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company’s public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

Originally published via Source Article.

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company’s public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

Originally published via Source Article.

TORONTO, 19 août 2026 (GLOBE NEWSWIRE) — Placements Vanguard Canada Inc. (le « gestionnaire ») annonce qu’elle a présenté une demande à la Bourse de Toronto (la « TSX ») afin de radier volontairement les parts du FNB mondial à volatilité minimale Vanguard (TSX : VVO) (le « FNB Vanguard »). Sous réserve de l’approbation de la TSX, le gestionnaire s’attend à ce que les parts du FNB Vanguard cessent d’être négociées à la TSX et soient radiées de sa cote après la fermeture des bureaux le 29 octobre 2026 (la « date de radiation »), et que le FNB Vanguard soit dissous avec prise d’effet le 3 novembre 2026 (la « date de dissolution »).

Originally published via Source Article.

A phased roadmap with a major international polyester materials producer begins with a contemplated commercial facility in the tens of millions of pounds annually and creates a conditional pathway toward potential multi-facility scale measured in billions.

A phased roadmap with a major international polyester materials producer begins with a contemplated commercial facility in the tens of millions of pounds annually and creates a conditional pathway toward potential multi-facility scale measured in billions.

Originally published via Source Article.